TM Owner Novartis
Vanrafia 0.75mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Vanrafia (atrasentan) is an endothelin receptor antagonist indicated for the treatment of chronic kidney disease (CKD) in adult patients to reduce the risk of kidney disease progression and cardiovascular events.
- Atrasentan works by blocking endothelin type A receptors, reducing glomerular hyperfiltration and proteinuria.
- It is used in patients with CKD stages 3b to 4 with albuminuria (urine protein), typically in combination with standard renin-angiotensin-aldosterone system (RAAS) inhibitors such as ACE inhibitors or angiotensin II receptor blockers (ARBs).
- The drug was approved by the FDA based on demonstrated slowing of kidney disease progression.
- Treatment requires monitoring of kidney function, potassium levels, and hemoglobin.
Side Effects
- The most common adverse reactions include fluid retention and peripheral edema (swelling in legs and feet) occurring in more than 30% of patients.
- Anemia (low hemoglobin) is frequent and requires periodic monitoring.
- Hyperkalemia (elevated potassium levels) is a serious concern and occurs in a significant proportion of patients.
- Orthostatic hypotension (dizziness upon standing) and weight gain are common.
- Serious reactions include congestive heart failure exacerbation and acute kidney injury.
- Headache and nasopharyngitis occur in 5 to 10% of users.
- Patients must report weight gain exceeding 3 to 5 pounds daily, shortness of breath, or severe ankle swelling immediately.
Precautions & Warnings
- Atrasentan has a boxed warning for fluid retention and heart failure—do not use in patients with New York Heart Association (NYHA) Class III or IV heart failure or uncontrolled systemic hypertension.
- Close monitoring of serum potassium and creatinine is mandatory, particularly in patients with baseline hyperkalemia or eGFR less than 30 mL/min.
- Atrasentan is contraindicated in pregnancy (Category X) and effective contraception is required for women of reproductive potential.
- Breastfeeding is not recommended.
- Monitor hemoglobin regularly as anemia is common.
- Adjust RAAS inhibitor doses if hyperkalemia develops.
- Avoid concurrent use with NSAIDs due to worsening renal function and hyperkalemia risk.
- Use caution in hepatic impairment.
Avoid Interactions
- NSAIDs (ibuprofen, naproxen, indomethacin) increase risk of acute kidney injury and hyperkalemia when combined with atrasentan—avoid or use with extreme caution and close monitoring.
- ACE inhibitors and ARBs may additively increase potassium levels; monitor serum potassium closely.
- Other potassium-elevating drugs (potassium supplements, spironolactone, trimethoprim) increase hyperkalemia risk.
- CYP3A4 inhibitors may increase atrasentan levels; no dose adjustment is currently recommended.
- Cyclosporine increases atrasentan exposure.
- Tell your healthcare provider about all medications, especially those affecting kidney function or potassium.
References
Frequently Asked Questions
Vanrafia (atrasentan) treats chronic kidney disease (CKD) to slow disease progression and reduce heart attack and stroke risk. It is an endothelin receptor blocker that reduces kidney damage in patients with CKD stages 3 to 4 who also have protein in their urine. Vanrafia is taken as a tablet once daily.
Vanrafia 0.75 mg is taken orally once daily, with or without food. The standard dose is one 0.75 mg tablet daily. Swallow the tablet whole with water. Take it at the same time each day. Do not skip doses, but if you miss a dose, take it as soon as you remember unless it is nearly time for the next dose.
Common side effects include swelling in the legs and ankles, anemia, dizziness upon standing, and weight gain. Vanrafia has a boxed warning for fluid retention and heart failure—tell your doctor immediately if you experience rapid weight gain, shortness of breath, or severe swelling.
Avoid NSAIDs like ibuprofen and naproxen, which worsen kidney function when combined with Vanrafia. Do not use potassium supplements without medical advice. Inform your doctor of all medications, as several drugs interact dangerously with atrasentan, especially those affecting kidney function.
Your doctor will regularly monitor potassium, creatinine, hemoglobin, and liver function during Vanrafia treatment. These tests check for dangerous potassium levels (which can cause heart problems), kidney function decline, anemia development, and liver side effects. Testing frequency is typically monthly initially, then every 3 months.
No, Vanrafia cannot be used in pregnancy and may harm the fetus. Women of reproductive age must use effective contraception while taking Vanrafia and for 28 days after stopping. Breastfeeding is not recommended. Discuss family planning with your doctor before starting treatment.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
